New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

Rhea-AI Summary

Roche announced significant results from its phase III REGENCY trial of Gazyva/Gazyvaro in treating lupus nephritis, published in the New England Journal of Medicine. The study showed that 46.4% of patients receiving Gazyva/Gazyvaro plus standard therapy achieved complete renal response (CRR) at 76 weeks, compared to 33.1% with standard therapy alone.

The treatment demonstrated consistent benefits across patient subgroups and showed improvements in complement levels and reductions in disease activity markers. Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a phase III study to show CRR benefit. The safety profile aligned with previous observations in hematology-oncology indications.

Key secondary endpoints revealed higher proteinuric response rates and better CRR with successful corticosteroid reduction in the Gazyva/Gazyvaro group. The drug previously received FDA Breakthrough Therapy Designation in 2019 based on phase II NOBILITY study data.

Positive

• 46.4% CRR achievement rate with Gazyva/Gazyvaro vs 33.1% for standard therapy (13.4% improvement)
• Statistically significant improvement in proteinuric response (55.5% vs 41.9%)
• Lower death or renal-related events (18.9% vs 35.6%)
• Successful reduction in corticosteroid use while maintaining efficacy
• FDA Breakthrough Therapy Designation already received

Negative

• Some secondary endpoints did not meet statistical significance (eGFR change, ORR at Week 50, FACIT-F change)

• Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone¹
• Analysis showed consistent CRR benefit across patient subgroups, highlighting potential to treat a broad patient population with high unmet need¹
• Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a phase III study to demonstrate CRR benefit,¹ which is associated with preservation of kidney function and delay or prevention of end-stage kidney disease

Basel, 7 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published in the New England Journal of Medicine.¹ The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of complete renal response (CRR), showing that 46.4% of people treated with Gazyva/Gazyvaro plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved CRR at 76 weeks compared with 33.1% of people treated with standard therapy alone (adjusted difference 13.4%, 95% CI, 2.0%-24.8%; P=0.0232). This was accompanied by clinically meaningful improvements in complement levels and reductions in anti-dsDNA, markers of disease activity and inflammation.¹

Data were presented at the World Congress of Nephrology (WCN) 2025 and are being shared with health authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency.

“The fact that nearly half of lupus nephritis patients achieved a complete renal response, together with clinically meaningful benefits observed consistently across subgroups, indicates superior disease control with Gazyva/Gazyvaro compared to standard treatment alone,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Lupus nephritis disproportionately affects younger women, mostly women of colour, often leading to end-stage kidney disease. Our goal is to address this urgent need by providing a more effective treatment option.”

“The positive REGENCY study results confirmed the findings of an earlier trial that administration of obinutuzumab, a therapy which targets B cells, benefitted patients with lupus nephritis more than standard treatment alone,” said Dr. Richard Furie, the Marilyn and Barry Rubenstein Chair in Rheumatology and Chief of the Division of Rheumatology at Northwell Health, US. “It is also gratifying to see that patients who received obinutuzumab were not only more likely to achieve the desired outcome but were able to taper corticosteroids at the same time.”

Gazyva/Gazyvaro’s safety profile was consistent with the well-characterised profile observed in its haematology-oncology indications. Key secondary endpoints showed that at week 76, patients who received Gazyva/Gazyvaro plus standard therapy were more likely to achieve CRR, with a successful reduction of corticosteroid use than standard therapy alone.¹ In addition, a higher proportion of patients showed improvement in proteinuric response when treated with Gazyva/Gazyvaro plus standard therapy versus standard therapy alone.¹ These endpoints are important indicators for achieving better disease control in lupus nephritis. As seen in pre-specified subgroup analyses, a benefit in CRR with Gazyva/Gazyvaro over standard therapy alone was consistent across all subgroups of patients, including indicators of more active lupus nephritis, Class IV lupus nephritis, concomitant Class V disease, higher baseline proteinuria levels, and/or greater serologic activity.¹

Further results for key secondary endpoints can be found in the table below and additional post hoc analysis is ongoing.

Key secondary endpoints	Obinutuzumab (n=135) Response % (95% CI)	Placebo (n=136) Response % (95% CI)	Treatment Difference (95% CI)	P value
CRR with prednisone taper (prednisone ≤7.5 mg/day Week 64 through Week 76)	42.7 (34.3, 51.1)	30.9 (23.1, 38.7)	11.9 (0.6, 23.2)	0.0421
Proteinuric response at Week 76 (UPCR <0.8 g/g)	55.5 (47.1, 64.0)	41.9 (33.6, 50.2)	13.7 (2.0, 25.4)	0.0227
Change in eGFR from baseline to Week 76, adjusted mean	2.31 (2.71)	-1.54 (2.71)	3.84 (-1.83, 9.51)	0.1842
Death or renal-related events through Week 76	18.9 (12.1, 25.6)	35.6 (27.5, 43.8)	-16.83 (-27.4, -6.2)	0.0026*
ORR at Week 50	59.1 (50.8, 67.4)	50.7 (42.2, 59.2)	8.4 (-3.4, 20.1)	0.1670
Change in FACIT-F from baseline  to Week 76, adjusted mean	1.8 (1.2)	3.1 (1.2)	-1.4 (-3.9, 1.2)	0.2991

* Statistical significance cannot be claimed as endpoints earlier in the hierarchy were not met


Lupus nephritis is a potentially life-threatening manifestation of an autoimmune disease that affects approximately 1.7 million people worldwide, predominantly women, mostly of colour and childbearing age.^2-5 Despite current treatment options, up to a third of people will develop end-stage kidney disease within 10 years, where dialysis or transplant are the only available options and the risk of mortality is high.⁶

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a CRR benefit in a randomised phase III study in lupus nephritis.¹ Based on data from the phase II NOBILITY study, Gazyva/Gazyvaro was granted Breakthrough Therapy Designation by the US FDA in 2019.⁷ In addition to REGENCY, Gazyva/Gazyvaro is being investigated in children and adolescents with lupus nephritis, people with membranous nephropathy, childhood-onset idiopathic nephrotic syndrome and systemic lupus erythematosus, an autoimmune disease that commonly affects the kidneys and can lead to lupus nephritis.^8-11

About the REGENCY study
REGENCY [NCT04221477] is a phase III, randomised, double-blind, placebo-controlled, multicentre study investigating the efficacy and safety of Gazyva®/Gazyvaro® (obinutuzumab) plus standard therapy (mycophenolate mofetil and glucocorticoids) in people with active/chronic International Society of Nephrology/Renal Pathology Society 2003 proliferative Class III or IV lupus nephritis, with or without Class V. The study enrolled 271 people, who were randomised 1:1 to receive either biannual intravenous dosing of Gazyva/Gazyvaro plus standard therapy or placebo plus standard therapy. REGENCY was designed based on robust phase II data and conducted during the COVID-19 pandemic. The study population was representative of the real-world population of people with lupus nephritis. The primary endpoint was the proportion of people who achieved a complete renal response (CRR) at 76 weeks. Key secondary endpoints included the proportion of people who achieved CRR at week 76 with successful reduction of corticosteroid use (prednisone taper); the proportion who achieved proteinuric response at 76 weeks; mean change in estimated glomerular filtration rate at 76 weeks; mean change in FACIT-F at week 76; death or renal-related events through week 76 and overall renal response at 50 weeks. Safety and tolerability were also assessed.

About Gazyva/Gazyvaro in kidney diseases
Gazyva®/Gazyvaro® (obinutuzumab) is a Type II engineered humanised monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells.¹² In lupus nephritis, disease-causing B cells drive persistent inflammation that damages the kidneys.¹³ We can target an underlying cause of lupus nephritis to help gain better control of the disease by depleting disease-causing B cells. Data suggest that Gazyva/Gazyvaro depletes disease-causing B cells, helping to limit further damage to the kidneys and potentially preventing or delaying progression to end-stage kidney disease.^12-14

Gazyva/Gazyvaro is already approved in 100 countries for various types of lymphoma. In the United States, Gazyva is part of a collaboration between Genentech and Biogen.

About lupus nephritis
Lupus nephritis is a potentially life-threatening manifestation of systemic lupus erythematosus, an autoimmune disease that commonly affects the kidneys.² Lupus nephritis affects approximately 1.7 million people worldwide. In lupus nephritis, disease-causing B cells drive persistent inflammation that damages the kidneys.^3,4 Lupus nephritis has a profound impact on the lives and outlook of those affected; even with the latest treatments, the damage to the kidneys usually gets worse over time, with up to a third of people progressing to end-stage kidney disease within 10 years, where the only options are dialysis or transplant, and the risk of mortality is high.⁶ Lupus nephritis predominantly affects women, mostly women of colour and usually of childbearing age.⁵ Currently, there is no cure.⁶

About Roche in kidney diseases
For 20 years, we have combined innovation, scientific expertise and commitment to patients to address unmet needs in kidney diseases. Our industry-leading pipeline includes several ongoing phase I-III clinical studies of immune-mediated investigational therapies with the aim of bringing innovative new treatment options to people living with kidney and kidney-related diseases, including lupus nephritis, membranous nephropathy, immunoglobulin A nephropathy, childhood-onset idiopathic nephrotic syndrome and systemic lupus erythematosus (SLE), an autoimmune disease that can lead to lupus nephritis.

Our pipeline also includes Sefaxersen (ASO factor B), an antisense oligonucleotide therapy being investigated in people with primary immunoglobulin A nephropathy at high risk of progression, Lunsumio® (mosunetuzumab), a first-in-class CD20xCD3 T-cell engaging bispecific antibody being investigated in SLE, RG6382, a CD19xCD3 T-cell engaging bispecific antibody being investigated in SLE, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T therapy being investigated in SLE.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Furie RA, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. NEJM. [Internet; cited February 2025]. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965.
[2] Hocaoglu et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades—The Lupus Midwest Network (LUMEN). Arthritis Rheumatol. 202;75(4):567–73.
[3] Tian J, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351-56.
[4] Hoi A, et al. Systemic lupus erythematosus. The Lancet. 2024;403(10441):2326-38.
[5] Anders HJ, et al. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9.
[6] Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Nat Rev Rheumatol. 2023;19:227-38.
[7] Roche. FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis. 2019. [Internet, cited February 2025]. Available from: https://www.roche.com/investors/updates/inv-update-2019-09-18.
[8] Clinicaltrials.gov. A study to evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab in adolescents with active class III or IV lupus nephritis and the safety and PK of obinutuzumab in pediatric participants (POSTERITY). [Internet; cited February 2025]. Available from: https://clinicaltrials.gov/study/NCT05039619.
[9] Clinicaltrials.gov. A study evaluating the efficacy and safety of obinutuzumab in participants with primary membranous nephropathy (MAJESTY). [Internet; cited February 2025]. Available from: https://clinicaltrials.gov/study/NCT04629248
[10] Clinical trials.gov. A study to evaluate the efficacy and safety of obinutuzumab versus MMF in participants with childhood onset idiopathic nephrotic syndrome (INShore). [Internet; cited February 2025]. Available from: https://clinicaltrials.gov/study/NCT05627557.
[11] Clinicaltrials.gov. A study to evaluate the efficacy and safety of obinutuzumab in participants with systemic lupus erythematosus (ALLEGORY). [Internet; cited February 2025]. Available from: https://clinicaltrials.gov/study/NCT04963296.
[12] Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-42.
[13] Atisha-Fregoso Y, et al. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12):e149095.
[14]  Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-7.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Sileia Urech Phone: +41 79 935 81 48
Nathalie Altermatt Phone: +41 79 771 05 25	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Nina Mählitz Phone: +41 79 327 54 74	Kirti Pandey Phone: +49 172 6367262
Yvette Petillon Phone: +41 79 961 92 50	Dr Rebekka Schnell Phone: +41 79 205 27 03

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• 20250207_REGENCY NEJM

FAQ

What were the primary results of Roche's (RHHBY) REGENCY trial for Gazyva/Gazyvaro?

The trial showed 46.4% of patients on Gazyva/Gazyvaro plus standard therapy achieved complete renal response at 76 weeks, compared to 33.1% with standard therapy alone, representing a 13.4% improvement.

How did Gazyva/Gazyvaro affect death and renal-related events in the RHHBY lupus nephritis trial?

Patients treated with Gazyva/Gazyvaro showed significantly lower rates of death or renal-related events (18.9%) compared to standard therapy (35.6%), a reduction of 16.83%.

What regulatory status has Roche's (RHHBY) Gazyva/Gazyvaro achieved for lupus nephritis?

Gazyva/Gazyvaro received FDA Breakthrough Therapy Designation in 2019 based on data from the phase II NOBILITY study.

What secondary endpoints did Roche's (RHHBY) Gazyva/Gazyvaro achieve in the REGENCY trial?

The drug showed improved proteinuric response (55.5% vs 41.9%) and better CRR with successful corticosteroid reduction, though some secondary endpoints like eGFR change and ORR at Week 50 did not meet statistical significance.